^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HER3-targeted antibody-drug conjugate

    Related drugs:
    1d
    A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=375, Recruiting, BioNTech SE | Trial completion date: Mar 2028 --> Aug 2028
    Trial completion date • First-in-human
    |
    pumitamig (BNT327)
    6d
    DB-1310-O-1001: A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=1000, Recruiting, DualityBio Inc. | Trial completion date: Aug 2026 --> Apr 2028 | Trial primary completion date: Aug 2026 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    Herceptin (trastuzumab) • Tagrisso (osimertinib) • capecitabine • DB-1310
    7d
    JS212 Combination Therapies in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial
    |
    capecitabine • oxaliplatin
    8d
    Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC (clinicaltrials.gov)
    P1, N=288, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • Tevimbra (tislelizumab-jsgr) • Ivesa (firmonertinib) • Yidafan (ivonescimab)
    8d
    A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cance (clinicaltrials.gov)
    P3, N=562, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • etoposide IV • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    11d
    Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR L858R • EGFR exon 19 deletion • ALK fusion
    |
    carboplatin • Loqtorzi (toripalimab-tpzi)
    11d
    The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study. (PubMed, Medicina (Kaunas))
    Of 52 patients (55.8% female; mean age 64.5 years), 59.6% received chemotherapy and 40.4% received an EGFR TKI as first-line treatment; erlotinib constituted 71.2% of targeted therapies. These results suggest that HER3 expression may warrant further investigation as a candidate biomarker for treatment sequencing decisions and as a potential therapeutic target in EGFR-mutant NSCLC. Prospective studies evaluating chemotherapy-TKI sequencing and HER3-directed agents such as patritumab deruxtecan (HER3-DXd) in HER3-positive patients are needed to confirm these preliminary observations.
    Retrospective data • Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • EGFR expression • ERBB3 positive
    |
    erlotinib • patritumab deruxtecan (U3-1402)
    18d
    A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=280, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial
    |
    5-fluorouracil • Loqtorzi (toripalimab-tpzi)
    18d
    A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P3, N=498, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • carboplatin • ruzaltatug rezetecan (SHR-A2009)
    20d
    A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=480, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • AWT020
    28d
    YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • BNT326
    29d
    A Study of YL202 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=100, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BNT326